Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells

Oncology Letters

Volumn 8, Issue 5, 2014, Pages 2086-2092

  Xia, Chen ^a   Ye, Fugui ^b   Hu, Xin ^c   Li, Zhengdong ^a   Jiang, Beiqi ^a   Fu, Yun ^a   Cheng, Xiaolin ^a   Shao, Zhiming ^c   Zhuang, Zhigang ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Breast neoplasms; Cytidine deaminase; DNA damage; Gemcitabine; Liver kinase B1

Indexed keywords

CYTIDINE DEAMINASE; GEMCITABINE; LIVER KINASE B1; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHEMOSENSITIVITY; CLONOGENESIS; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84907153402     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2446     Document Type: Article

References (28)

1. Mehenni H, Gehrig C, Nezu J, et al: Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 63: 1641-1650, 1998.
2. Lim W, Olschwang S, Keller JJ, et al: Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 126: 1788-1794, 2004.
3. Hearle N, Schumacher V, Menko FH, et al: Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12: 3209-3215, 2006.
4. Fenton H, Carlile B, Montgomery EA, et al: LKB1 protein expression in human breast cancer. Appl Immunohistochem Mol Morphol 14: 146-153, 2006.
5. Ji H, Ramsey MR, Hayes DN, et al: LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810, 2007.
6. Sanchez-Cespedes M, Parrella P, Esteller M, et al: Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659-3662, 2002.
7. Wang ZJ, Churchman M, Campbell IG, et al: Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer 80: 70-72, 1999.
8. Ylikorkala A, Avizienyte E, Tomlinson IP, et al: Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet 8: 45-51, 1999.
9. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234, 2009.
10. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27: 5513-5518, 2009.
11. Chan S, Romieu G, Huober J, et al: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 27: 1753-1760, 2009.
12. Mini E, Nobili S, Caciagli B, Landini I and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 17: v7-v12 (Suppl 5), 2006.
13. Wong A, Soo RA, Yong WP and Innocenti F: Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev 41: 77-88, 2009.
14. Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Update 5: 19-33, 2002.
15. Katajisto P, Vallenius T, Vaahtomeri K, et al: The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta 1775: 63-75, 2007.
16. Zhuang ZG, Di GH, Shen ZZ, Ding J and Shao ZM: Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol Cancer Res 4: 843-849, 2006.
17. Bonner WM, Redon CE, Dickey JS, et al: GammaH2AX and cancer. Nature Rev Cancer 8: 957-967, 2008.
18. Mah LJ, El-Osta A and Karagiannis TC: gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 24: 679-686, 2010
19. Al-Ejeh F, Darby JM and Brown MP: The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs. Clin Cancer Res 13: 5509s-5518s, 2007.
20. Dufau I, Frongia C, Sicard F, et al: Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer. BMC Cancer 12: 15, 2012.
21. Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann Rev Biochem 73: 39-85, 2004.
22. Lee JH and Paull TT: ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308: 551-554, 2005.
23. Zou L and Elledge SJ: Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300: 1542-1548, 2003.
24. Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108: 73-112, 2010.
25. Lee JH and Paull TT: Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science 304: 93-96, 2004.
26. Bardenheuer W, Lehmberg K, Rattmann I, et al: Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 19: 2281-2288, 2005.
27. Bergman AM, Eijk PP, Ruiz van Haperen VW, et al: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65: 9510-9516, 2005.
28. Nakahira S, Nakamori S, Tsujie M, et al: Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120: 1355-1363, 2007.